Tafamidis
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Tafamidis
Tafamidis: Known uses and market status in Canada
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Tafamidis, so there is currently no new predicted indication. The drug’s recorded uses are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 4 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| amyloidosis | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| ah amyloidosis |
| al amyloidosis |
| attrv122i amyloidosis |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 02517841 | VYNDAMAX | Valid |
Safety Considerations
Drug Interactions (13 records; one is the target-binding entry for TTR rather than an interacting drug):
- Major: Ozanimod
- Moderate: Rosuvastatin, Deferasirox, Eltrombopag, Lusutrombopag, Artesunate, Axitinib, Methotrexate, Irinotecan (including liposomal), Belinostat, Imatinib
Please refer to the package insert for warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.